We learned today that the Court of Appeals for the Federal Circuit has modified its opinion of August 9, 2000 in which it found the 2003 Prozac patent invalid for double patenting.
In essence, the Court has again ruled that the patent is invalid for double patenting, but has used a different analysis to reach this conclusion.
We intend to seek legal review of today's decision.
Although it is possible that the legal review process could delay Barr from entering the market on August 3, we continue to plan for Barr launching generic fluoxetine at that time.

CAFC Ruling on 2003 Prozac Patent
